ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
196.6 EUR
-0.2 (-0.1%)
4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year 4AB was profitable.
In the past year 4AB had a positive cash flow from operations.
Each year in the past 5 years 4AB has been profitable.
Each year in the past 5 years 4AB had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.75%, 4AB is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
The Return On Invested Capital of 4AB (15.64%) is better than 92.59% of its industry peers.
4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 11.80%.
The last Return On Invested Capital (15.64%) for 4AB is above the 3 year average (13.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
4AB has a better Profit Margin (3.94%) than 77.78% of its industry peers.
4AB's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 33.05%, 4AB belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
4AB's Operating Margin has declined in the last couple of years.
The Gross Margin of 4AB (71.16%) is better than 61.73% of its industry peers.
4AB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
4AB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
4AB has about the same amout of shares outstanding than it did 1 year ago.
4AB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 4AB is higher compared to a year ago.
2.2 Solvency
4AB has an Altman-Z score of 2.48. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
4AB has a better Altman-Z score (2.48) than 70.37% of its industry peers.
The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 4AB (3.49) is better than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.48 |
ROIC/WACC1.88
WACC8.32%
2.3 Liquidity
4AB has a Current Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.72, 4AB is doing worse than 76.54% of the companies in the same industry.
4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.60, 4AB is doing worse than 77.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
The Earnings Per Share has been growing slightly by 2.51% on average over the past years.
The Revenue has been growing slightly by 7.40% in the past year.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
The Earnings Per Share is expected to grow by 13.69% on average over the next years. This is quite good.
4AB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.42% yearly.
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.69%
Revenue Next Year8.74%
Revenue Next 2Y9.13%
Revenue Next 3Y8.7%
Revenue Next 5Y7.42%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.45, 4AB is valued on the expensive side.
80.25% of the companies in the same industry are more expensive than 4AB, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.51, 4AB is valued at the same level.
The Price/Forward Earnings ratio is 15.89, which indicates a correct valuation of 4AB.
92.59% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (23.13), we can say 4AB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.45 | ||
| Fwd PE | 15.89 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 4AB is valued a bit cheaper than the industry average as 76.54% of the companies are valued more expensively.
86.42% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.74 | ||
| EV/EBITDA | 16.72 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 4AB may justify a higher PE ratio.
A more expensive valuation may be justified as 4AB's earnings are expected to grow with 16.87% in the coming years.
PEG (NY)3.35
PEG (5Y)9.74
EPS Next 2Y19.85%
EPS Next 3Y16.87%
5. Dividend
5.1 Amount
4AB has a Yearly Dividend Yield of 3.01%.
Compared to an average industry Dividend Yield of 0.74, 4AB pays a better dividend. On top of this 4AB pays more dividend than 96.30% of the companies listed in the same industry.
4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.01% |
5.2 History
The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
FRA:4AB (12/30/2025, 7:00:00 PM)
196.6
-0.2 (-0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.96%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap347.47B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts77.89
Price Target212.95 (8.32%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.01% |
Yearly Dividend5.3
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)-0.97%
PT rev (3m)12.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)0.93%
EPS NY rev (3m)-11.46%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)0.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.45 | ||
| Fwd PE | 15.89 | ||
| P/S | 6.85 | ||
| P/FCF | 20.74 | ||
| P/OCF | 19.57 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.72 |
EPS(TTM)8.04
EY4.09%
EPS(NY)12.37
Fwd EY6.29%
FCF(TTM)9.48
FCFY4.82%
OCF(TTM)10.04
OCFY5.11%
SpS28.72
BVpS-1.27
TBVpS-44.58
PEG (NY)3.35
PEG (5Y)9.74
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.48 |
F-Score7
WACC8.32%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.69%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.74%
Revenue Next 2Y9.13%
Revenue Next 3Y8.7%
Revenue Next 5Y7.42%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.3%
EBIT Next 3Y15.61%
EBIT Next 5Y11.36%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status for 4AB stock?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for 4AB stock?
The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.
How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?
The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.